Read by QxMD icon Read

colorectal peritoneal metastasis

Shuhei Mayanagi, Kosuke Kashiwabara, Michitaka Honda, Koji Oba, Toru Aoyama, Mitsuro Kanda, Hiromichi Maeda, Chikuma Hamada, Sotaro Sadahiro, Junichi Sakamoto, Shigetoyo Saji, Takaki Yoshikawa
BACKGROUND: Most previous reports to analyze risk factors for peritoneal recurrence in patients with colon cancer have been observational studies of a population-based cohort. OBJECTIVE: This study aimed to determine the risk factors for peritoneal recurrence in patients with stage II to III colon cancer who underwent curative resection. DESIGN: This was a pooled analysis using a combined database obtained from 3 large phase III randomized trials (N = 3714)...
March 20, 2018: Diseases of the Colon and Rectum
Rea Lo Dico, Annemilai Tijeras-Raballand, Philippe Bonnin, Jean Marie Launay, Rachid Kaci, Cynthia Pimpie, Brice Malgras, Anthony Dohan, Gianluigi Maria Lo Dico, Marc Pocard
BACKGROUND: Curative surgery of synchronous peritoneal metastases (PM) and colorectal liver metastases (LM) has been recently investigated as feasible option. When synchronous peritoneal and liver resection is not achievable, the sequence of the surgery remains unknown. Our hypothesis was that liver resection (LR) promotes peritoneal growth resulting in a non-resectable PM. We sought to analyse the effects of major LR and liver regeneration after hepatectomy in a murine model of PM and the associated angiogenesis...
January 31, 2018: European Journal of Surgical Oncology
Lee Shyang Kyang, Sarah J Valle, Nayef A Alzahrani, David L Morris
Peritoneal metastasis (PM) following primary resection of colorectal cancer is common. The combined use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy has significantly improved the survival outcome of patients with colorectal PM (CRPM). Diagnosing and treating early PM is essential as its extent is correlated with poorer outcomes. There are two novel therapies - second-look surgery and synchronous hyperthermic intraperitoneal chemotherapy - that are proposed to prophylactically treat or intervene early in the disease process to reduce the incidence and adverse outcomes associated with PM...
March 6, 2018: ANZ Journal of Surgery
Elisa Schmoeckel, Thomas Kirchner, Doris Mayr
The differentiation between a primary mucinous ovarian neoplasm and an extra-ovarian metastasis in the ovary is often challenging in the histopathologic practice. Among various ovarian metastases from the gastro-intestinal tract the low-grade appendiceal mucinous neoplasm (LAMN) is an important differential diagnosis to consider particularly in case of pseudomyxoma peritonei. A newly recognized marker in the routine diagnostic of a mucinous neoplasm in the ovary is SATB2 (Special AT-rich sequence-binding protein 2)...
December 14, 2017: Pathology, Research and Practice
Yoji Nishimura, Shinsuke Kazama, Yusuke Nishizawa, Takashi Takenoya, Michitoshi Takano, Hiroaki Ishii, Yoshiyuki Kawashima, Hirohiko Sakamoto
We experienced 3 impressive colorectal cancer patients who developed peritoneal recurrences and underwent surgery several times and survived for more than 5 years. Case No. 1 was of a 44-year-old woman who underwent right hemicolectomy for her stage II A ascending colon cancer. She developed left ovarian metastasis, which was resected 3 years later. Five years later, she developed a pelvic peritoneal recurrence, which was resected successfully. Thirteen years later, she is doing well. Case No. 2 was of a 61-year-old man who underwent transverse colectomy for his stage II B colon cancer...
February 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Sabine Heublein, Markus Albertsmeier, David Pfeifer, Lisa Loehrs, Alexandr V Bazhin, Thomas Kirchner, Jens Werner, Jens Neumann, Martin Kurt Angele
BACKGROUND: Though peritoneal carcinomatosis reflects a late stage of colorectal cancer (CRC), only few patients present with synchronous or metachronous liver metastases alongside their peritoneal carcinomatosis. It is hypothesized that this phenomenon may be causally linked to molecular characteristics of the primary CRC. This study used miRNA profiling of primary CRC tissue either metastasized to the liver, to the peritoneum or not metastasized at all thus to identify miRNAs potentially associated with defining the site of metastatic spread in CRC...
February 20, 2018: BMC Cancer
Yutaka Yonemura, Emel Canbay, Shouzou Sako, Satoshi Wakama, Haruaki Ishibashi, Masamitsu Hirano, Akiyoshi Mizumoto, Nobuyuki Takao, Masumi Ichinose, Kousuke Noguchi, Shunsuke Motoi, Yang Liu, Yan Li, Keizou Taniguchi
To analyze the role of cytoreductive surgery(CRS)plus perioperative chemotherapy on the survival of colorectal cancer(CRC)patients with metachronous peritoneal metastasis(PM). A comprehensive treatment consisting of neoadjuvant chemotherapy plus CRS was performed in 291 CRC patients. Among the 291, 142 and 149 patients had synchronous and metachronous PM, respectively. The results showed no survival difference between the 2 groups. Median survival time(MST)of patients with metachronous PM with complete cytoreduction(CCR-0), small bowel(SB)-PCIC2, PCIC14 and differentiated histologic type ranged from 3...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Takuya Fujimoto, Nobuaki Suzuki, Shinobu Tomochika, Hironori Tanaka, Hiroto Matsui, Kazuhiko Sakamoto, Shigeru Takeda, Shigeru Yamamoto, Shigefumi Yoshino, Shoichi Hazama, Haruaki Ishibashi, Yutaka Yonemura, Tomio Ueno, Hiroaki Nagano
We report a case of colorectal cancer with peritoneal dissemination and liver metastasis that achieved R0 resection by preoperative chemotherapy and CRS plus HIPEC. A 33-year-old man presented with a complaint of abdominal bloating. After further examination, he was diagnosed with transverse colon cancer with peritoneal dissemination and liver metastasis. After 9 courses of preoperative XELOX plus cetuximab and 4 courses of preoperative XELIRI plus bevacizumab, he underwent transverse colon resection, peritoneal resection, and HIPEC(MMC 20mg/4,000mL physiological saline, 40mins)...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Katsuya Ohta, Masakazu Ikenaga, Masami Ueda, Ryuji Iwaki, Tae Kinoshita, Kyoko Mishima, Kiyo Shindo, Yoshinao Chinen, Hiroaki Itakura, Takatoshi Takayama, Yujiro Tsuda, Shinsuke Nakashima, Shinichi Adachi, Shunji Endo, Terumasa Yamada
Malignant intractable ascites worsens not only patient symptoms but also their daily activities. It often leads to a patient discontinuing or postponing chemotherapy. In the present study, we introduced cell-free and concentrated ascites reinfusion therapy(CART)for malignant intractable ascites from colorectal cancer. Six patients underwent 12 CART treatments using AHF-WMO as the ascites filterand AHF-UP as the concentrator(Asahi Kasei Medical Co., Ltd.)from January 2014 to January 2017. The patients included 2 men and 4 women aged 67-89 years...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Masato Mito, Hitoshi Kameyama, Yoshifumi Shimada, Saki Yamada, Shinnosuke Hotta, Yuki Hirose, Ryoma Yagi, Yosuke Tajima, Mae Nakano, Takuma Okamura, Masato Nakano, Hiroshi Ichikawa, Masayuki Nagahashi, Jun Sakata, Toshifumi Wakai
The patient was a 73-year-old man with ascending colon cancer and synchronous liver metastases. A right hemicolectomy with a lymph node dissection was performed for the primary lesion. The resected specimen revealed a KRAS codon 12 mutation. After 6 courses of chemotherapy with capecitabine, oxaliplatin, and bevacizumab(Bv), we performed a partial hepatectomy and resection of the peritoneal dissemination. A computed tomography(CT)scan 5 months later revealed the recurrence of the liver metastases. After 8 courses of chemotherapy with 5-fluorouracil, Leucovorin, irinotecan, and Bv, we performed a partial hepatectomy...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Wenqiong Wu, Shipeng Yan, Xianzhen Liao, Haifang Xiao, Zhongxi Fu, Lizhang Chen, Jinsong Mou, Haibo Yu, Lian Zhao, Xiangguo Liu
The objective of this study was to provide an up-to-date summary of the current evidence that may be useful for updating guidelines. We comprehensively searched the published literatures and conferences for studies that compared curative with palliative treatments in colorectal cancer patients with peritoneal metastasis. The primary outcomes considered in this study were three- and five-year overall survival rates. We pooled data across studies and estimated summary effect sizes. Overall, patients who received curative treatments had improved three-year survival (hazard ratio (HR), 2...
December 22, 2017: Oncotarget
Hiroshi Nagata, Soichiro Ishihara, Junko Kishikawa, Hirofumi Sonoda, Koji Murono, Shigenobu Emoto, Manabu Kaneko, Kazuhito Sasaki, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa
Despite extensive research on cancer stem cells in colorectal cancer, the impact of stem cell markers on patient survival remains unclear, particularly in those with distant metastasis. In this study, we focused on colon cancer with peritoneal metastasis and investigated the association between the expression of CD133, aldehyde dehydrogenase-1 (ALDH1) and leucine-rich repeating G-protein coupled receptor-5 (Lgr5), and disease prognosis. Putative stem cell marker expression was immunohistochemically evaluated in samples from 142 primary tumours and 75 peritoneal nodules...
January 8, 2018: International Journal of Oncology
Chawalit Chayangsu, Siriporn Khunsri, Virote Sriuranpong, Suebpong Tanasanvimon
Background: Amphiregulin (AREG) is one of the epidermal growth factor receptor (EGFR) ligands and plays the important roles in tumor progression and metastasis. Upregulation of AREG in colorectal cancer (CRC) tissues has been shown to correlate with depth of tumor invasion, nerve invasion and liver metastasis. We sought to investigate a correlation of serum AREG in CRC with clinicopathological parameters. Methods: Patients with CRC receiving treatment at King Chulalongkorn Memorial Hospital during August 2013 to March 2014 were enrolled...
December 2017: Journal of Gastrointestinal Oncology
Mohammed Benlahfid, Wael Traboulsi, Frederic Sergent, Mohamed Benharouga, Khalid Elhattabi, Driss Erguibi, Mehdi Karkouri, Hicham Elattar, Abdelaziz Fadil, Yassine Fahmi, Touria Aboussaouira, Nadia Alfaidy
BACKGROUND: The highest risk factor for mortality among malignant tumors is metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor which biological activity is mediated via two G protein-coupled receptors, prokineticin receptor1 (PROKR1) and PROKR2. Recent studies suggested that EG-VEGF expression is deregulated in multiple cancers including colorectal cancer (CRC). METHODS: Using distinctive CRC and peritoneal carcinomatosis (PC) cohorts and a corresponding control cohort, we determined the circulating levels of EG-VEGF and its in situ expression, and that of its related receptors...
February 6, 2018: Cancer Biomarkers: Section A of Disease Markers
Tomokazu Kishiki, Brittany Lapin, Hiroyoshi Matsuoka, Takeshi Watanabe, Kohei Takayasu, Koichiro Kojima, Kenichi Sugihara, Tadahiko Masaki
BACKGROUND: After patients with stage IV colorectal cancer undergo curative surgical resection, there is a large risk for recurrence. To establish optimal surveillance guidelines, an understanding of the temporal risk factors for recurrence is necessary. OBJECTIVE: The primary aim of our study was to determine predictors for early (within 1 year), middle (1-2 years), and late (2 years or later) recurrence following curative resection in patients with stage IV colorectal cancer...
January 2018: Diseases of the Colon and Rectum
Ling Li, Rui Deng, Yi Su, Cheng Yang
Colorectal cancer has been one of the most common cancers in the worldwide. Poor patient compliance and serious side effects often associated with conventional therapy (e.g. surgery, radiation, and chemotherapy). Gene therapy may be an alternative strategy. Herein, we developed a dual-targeting nanoparticle with excellent gene transfection efficiency for gene therapy of peritoneal metastasis of colorectal cancer. This nanoparticle can facilitate efficient cellular uptake and promote penetration into nucleus...
October 27, 2017: Oncotarget
Xiangquan Kong, Xueqing Zhang, Yunxia Huang, Lirui Tang, Qingqin Peng, Jinluan Li
Background: Colorectal signet ring cell (SRC) carcinoma occurs rarely with a poor prognosis. The present study assessed the prognostic factors and predictive value of SRC ratio in colorectal mucinous adenocarcinoma (MAC) with SRCs (MAC-SRC). Patients and methods: A total of 95 consecutive colorectal MAC-SRC patients, confirmed pathologically from February 1987 to December 2015, were analyzed retrospectively in our institute. Clinical characteristics, pathological grade, TNM staging, and SRC ratio were assessed to identify the prognostic factors related to progression-free survival (PFS) and overall survival (OS)...
2017: Cancer Management and Research
Dai Shida, Shunsuke Tsukamoto, Hiroki Ochiai, Yukihide Kanemitsu
BACKGROUND: The National Comprehensive Cancer Network (NCCN) guidelines for colon cancer recently added the following footnote regarding the therapeutic strategy for peritoneal metastases: "If R0 resection can be achieved, surgical resection of isolated peritoneal disease may be considered at experienced centers." This study investigated the efficacy of R0 resection of peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy (HIPEC)...
October 23, 2017: Annals of Surgical Oncology
Paraskevas Stamopoulos, Nikolaos Machairas, Stylianos Kykalos, Afrodite Nonni, Gregory Kouraklis, Georgios C Sotiropoulos
Prolonged survival in patients suffering from colorectal cancer (CRC) may lead to the emergence of rare metastatic sites that are not well-documented in the literature. We herein describe a very rare case of an intraluminal small intestinal metastasis in a patient with previously resected CRC. A 71-year-old Caucasian male patient with a history of rectosigmoid junction cancer was initially treated with anterior resection. The tumor was classified as pT3pN0 (0/26) M0, stage II. Eighteen months after the primary surgery, local recurrence was detected in the presacral region, and the patient received combined image-guided radiotherapy and chemotherapy...
October 2017: Molecular and Clinical Oncology
Xicheng Wang, Qing Wei, Jing Gao, Jian Li, Jie Li, Jifang Gong, Yanyan Li, Lin Shen
BACKGROUND: The prognostic role of the V600E mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in metastatic colorectal cancer (mCRC) is well established, but the therapeutic regimen targeting this disease is lacking. This study aimed to analyze the clinicopathologic features of and treatment efficacy of commonly used regimens on BRAF-mutated mCRCs. METHODS: We collected and reviewed the medical records of mCRC patients treated at Peking University Cancer Hospital & Institute (Beijing, China) between July 2011 and July 2016...
October 16, 2017: Chinese Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"